Table 2.

PSA End Points by Treatment Arm

Treatment Arm	PSA (ng/mL)						Total
	≤ 0.2*		> 0.2 to ≤ 4.0		> 4.0†
	No.	%	No.	%	No.	%	No.	%
AD plus cixutumumab	42	40.0	17	16.2	46	43.8	105	100.0
AD alone	34	32.4	15	14.3	56	53.3	105	100.0
P	.16‡				.11‡		.17§

Abbreviations: AD, androgen deprivation; PSA, prostate-specific antigen.

^*Primary end point analysis comparing PSA ≤ 0.2 ng/mL between treatment arms.

^†Secondary end point analysis comparing PSA > 4.0 ng/mL between treatment arms.

^‡Fisher's exact test.

^§Extended Mantel-Haenszel test using integer scores for columns.